| Factor Information | |
|---|---|
| Data ID | 98 |
| Factor | uric acid |
| Description | Patients in whom an event occurred had high uric acid (63.5 (6–90) mmol/l versus 36.5 (1–88) mmol/l. |
| Biomarker | NA |
| Classification | E2 (physiological factor - biochemical index) |
| Association | |
|---|---|
| Application | prognosis |
| Objective | To access the risk factors associated with PAH-CHD of maternal outcomes. |
| p Value | 0.002 |
| OR | 1.005 |
| Conclusion | Maternal mortality and morbidity remain high in PAH-CHD patients, who should be counseled on the risks of pregnancy and managed in a tertiary multidisciplinary environment to improve prognosis. |
| Risk Factor | no influencing factor |
| CHD Type | |
|---|---|
| ID | 414 |
| CHD Type | isolated CHD/non-isolated CHD |
| CHD Subtype | ASD/VSD/PDA/ASD, VSD/ASD, PDA/VSD, PDA/VSD, ES/PDA, ES/VSD, CHD with PAH |
| Reference | |
|---|---|
| PMID | 30971116 |
| Year | 2019 |
| Title | Peripartum outcomes in a large population of women with pulmonary arterial hypertension associated with congenital heart disease. |
| Sample | ||
|---|---|---|
| Population | women (pregnancies) | |
| Source | electronic medical record system | |
| Region | Beijing,China | |
| Method | Logistic regression analysis | |
| Race | Asian | |
| Disease History | N/A | |
| Treatment History | Elective Cesarean section was performed in 95.7% of women, with intravertebral anesthesia in 93.6%. Fifty-one (54.2%) patients received pulmonary arterial hypertension therapies during pregnancy. | |
| Group | cases with combined endpoint of maternal death, severe heart failure, or pulmonary hypertensive crisis(Treatment) | cases without combined event of outcome(Control) |
| Number | 34 | N/A |
| Age | N/A | N/A |
| Gender (Male: Female) | 0:34 | N/A |
| Marker Level | 63.5(6–90) μmol/l | 36.5 (1–88) umol/l |
